Treatment of patients with hepatitis C virus genotype 3: Where are we now?
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez, Fred Poordad – 28 October 2015 – Watch a video presentation of this article
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez, Fred Poordad – 28 October 2015 – Watch a video presentation of this article
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez, Fred Poordad – 28 October 2015 – Watch a video presentation of this article
Nishita Patel, Santiago J. Muñoz – 28 October 2015 – Watch a video presentation of this article
David Semela – 28 October 2015 – Watch a video presentation of this article
Mette M. Lauridsen, James B. Wade, Jasmohan S. Bajaj – 28 October 2015 – Watch a video presentation of this article
Lin Fan, Kwame Owusu‐Edusei, Sarah F. Schillie, Trudy V. Murphy – 28 October 2015 – In an era of antiviral treatment, reexamination of the cost‐effectiveness of strategies to prevent perinatal hepatitis B virus (HBV) transmission in the United States is needed. We used a decision tree and Markov model to estimate the cost‐effectiveness of the current U.S. strategy and two alternatives: (1) Universal hepatitis B vaccination (HepB) strategy: No pregnant women are screened for hepatitis B surface antigen (HBsAg).
Lola M. Reid, Praveen Sethupathy – 27 October 2015
Stephan Urban – 26 October 2015
Francesco Tandoi, Mauro Salizzoni, Andrea Brunati, Francesco Lupo, Renato Romagnoli – 22 October 2015
Giovanni Targher, Christopher D. Byrne – 21 October 2015